Obesity management began to shift dramatically starting in 2014 with the first FDA approval of a GLP-1 receptor agonist (RA) for weight loss. But things really took off in 2021 with the approval of another medication to this class, semaglutide.

Join us for the next installment of CMA’s Virtual Grand Rounds—Virtual Grand Rounds: New Weight Loss Medications - Panacea or Pandora's Box—on Tuesday, March 12, 2024, at 12:00 p.m, to hear from experts about the evidence and real-world data on this new class of obesity medications.

And as always, we will hear from California State Epidemiologist Erica Pan, M.D., MPH, who will review the current status of COVID-19, influenza and other winter respiratory viruses.

The free one-hour webinar is open to all interested parties.   

Virtual Grand Rounds: Emerging Public Health Issues is a free and monthly series providing the latest patient management news and resources. The effort is a partnership between CMA and the California Health and Human Services Agency, with the California Academy of Physician Assistants and the Osteopathic Physicians and Surgeons of California.

If you are unable to attend the live event, it will be available for on-demand playback at cmadocs.org/grandrounds.